ER+/HER2- Breast Cancer Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), C

ER+/HER2- Breast Cancer emerging therapies such as KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others are expected to boost the ER+/HER2- Breast Cancer Market in the upcoming years.

DelveInsight has launched a new report on "ER+/HER2- Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the ER+/HER2- Breast Cancer, historical and forecasted epidemiology as well as the ER+/HER2- Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover latest insights into our ER+/HER2- Breast cancer market report https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the ER+/HER2- Breast Cancer Market Report:

In 2021, the total number of new breast cancer cases in the United States was 256,431. Among these, postmenopausal breast cancer accounted for 205,145 cases. In the same year, the distribution of breast cancer cases by stage was as follows: 164,116 localized, 74,365 regional, 15,386 distant, and 2,564 with unknown stage. These numbers are expected to rise during the forecast period.
Among the various subtypes of the disease (localized and regional), ER+/HER2- represented the largest patient group with 147,977 cases, followed by 24,325 cases of triple-negative breast cancer and 20,271 cases of ER+/HER2+. Conversely, HR-/HER2+ had the fewest cases.
Key ER+/HER2- Breast Cancer companies such as Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others are evaluating new drugs for ER+/HER2- Breast Cancer to improve the treatment landscape.
Promising ER+/HER2- Breast Cancer pipeline therapies in various stages of development include KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others.
Key benefits of the ER+/HER2- Breast Cancer market report:
ER+/HER2- Breast Cancer market report covers a descriptive overview and comprehensive insight of the ER+/HER2- Breast Cancer Epidemiology and ER+/HER2- Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The ER+/HER2- Breast Cancer market report provides insights on the current and emerging therapies.
ER+/HER2- Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The ER+/HER2- Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the ER+/HER2- Breast Cancer market.

Got queries? Click here to know more about the ER+/HER2- Breast Cancer Market Landscape https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

ER+/HER2- Breast Cancer Overview

Breast cancer develops when abnormal cancerous cells in the breast grow and multiply uncontrollably, forming a tumor. It typically begins in the breast's ducts or lobules. Cancer cells receive various signals that drive their growth, which can include hormones.

Hormone receptors are proteins that detect hormone signals and instruct the cancer cells to grow. When breast cancer cells are stimulated by estrogen, which promotes tumor growth, it is called estrogen receptor-positive (ER+) breast cancer. Similarly, when cells respond to progesterone, promoting growth, it is termed progesterone receptor-positive (PR+) breast cancer. Breast cancer that is either ER+ or PR+ is classified as hormone receptor-positive (HR+) breast cancer.

On the other hand, hormone receptor-negative (HR-) breast cancer occurs when cancer cells lack hormone receptors. These cells do not rely on estrogen or progesterone to grow.

Another key factor in breast cancer is the human epidermal growth factor receptor 2 (HER2), a gene responsible for regulating cell growth, division, and repair. The HER2 protein acts as a receptor on breast cells. HER2-positive (HER2+) breast cancer tests positive for this protein, and these cancers tend to grow more rapidly and are more likely to spread or recur compared to HER2-negative (HER2-) breast cancer. The HER2 status of a patient is determined through testing for the presence of the HER2 protein.

In HER2- negative breast cancer, cells do not have a significant amount of the HER2 protein on their surface. These cancer cells often grow more slowly and are less likely to spread or come back compared to HER2+ cells. Testing for HER2 can help guide treatment decisions.

ER+/HER2- Breast Cancer Treatment Market

Estrogen receptor (ER) expression is a key factor in predicting the effectiveness of hormonal therapy, as most human breast cancers are hormone-dependent and ER-positive. There are several types of anti-estrogenic treatments available for patients with early, advanced, or metastatic breast cancer, including selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders. However, ongoing clinical research is focused on combining anti-estrogenic therapies with targeted agents that block the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway or the cyclin-dependent kinase 4/6 (CDK4/6) pathway, which regulates the G1/S checkpoint of the cell cycle. These combinations are being studied for patients with hormone receptor-positive breast cancer who have experienced disease recurrence or progression.

Discover how the ER+/HER2- Breast cancer treatment market is growing https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

ER+/HER2- Breast Cancer Market Outlook

Breast cancer is the second most common cancer globally, with estrogen receptor-positive (ER+) breast cancer being the most prevalent type. About two-thirds of breast cancer cases are hormone receptor-positive (HR+), with the majority being ER+. These cancers are driven by estrogen, which stimulates their growth.

The stage of breast cancer is critical for treatment decisions. For women with Stage I, II, or III breast cancer, surgery is usually the primary treatment, often followed by radiation therapy. Chemotherapy, hormone therapy (tamoxifen or aromatase inhibitors), and HER2-targeted drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) are commonly used depending on the tumor's hormone receptor and HER2 status. For Stage I HR+ breast cancer, hormone therapy is typically recommended, while larger tumors may also require chemotherapy. HER2+ cancers generally receive trastuzumab as part of the treatment.

For Stage II breast cancer, systemic therapy (neoadjuvant or adjuvant) is recommended, often before or after surgery. Neoadjuvant therapy can shrink large tumors, allowing for breast-conserving surgery. Stage III cancers often require neoadjuvant chemotherapy, and HER2+ tumors are treated with trastuzumab and sometimes pertuzumab.

Current drugs include tamoxifen, aromatase inhibitors (letrozole, anastrozole, exemestane), luteinizing hormone-releasing hormone analogs (goserelin, leuprolide), and fulvestrant for patients resistant to previous treatments. Sequential hormone therapy is recommended until resistance develops, at which point chemotherapy may be necessary.

The pipeline for ER+/HER2- breast cancer includes several promising drugs in late- and mid-stage development, with key players like Radius Pharmaceuticals (Elacestrant), AstraZeneca (Camizestrant), Roche (Giredestrant), and others working on treatments that may reshape the market in the coming years.

Explore more about ER+/HER2- Breast cancer market @ https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

ER+/HER2- Breast Cancer Marketed Drugs:

KISQALI (ribociclib): Novartis
IBRANCE (palbociclib): Pfizer
AFINITOR (everolimus): Novartis
LYNPARZA (olaparib): AstraZeneca

ER+/HER2- Breast Cancer Emerging Drugs:

Elacestrant: Radius Pharmaceuticals
Giredestrant (RG6171, GDC-9545): Roche
Camizestrant (AZD9833): AstraZeneca
LY3484356 (imlunestrant): Eli Lilly
Lerociclib (EQ132): EQRx

Discover which ER+/HER2- Breast cancer drugs will boost the market in the upcoming years @ https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the ER+/HER2- Breast Cancer Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key ER+/HER2- Breast Cancer Companies: Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and others
Key ER+/HER2- Breast Cancer Therapies: KISQALI (ribociclib), IBRANCE (palbociclib), AFINITOR (everolimus), LYNPARZA (olaparib), Elacestrant, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), LY3484356 (imlunestrant), Lerociclib (EQ132), and others
ER+/HER2- Breast Cancer Therapeutic Assessment: ER+/HER2- Breast Cancer current marketed and ER+/HER2- Breast Cancer emerging therapies
ER+/HER2- Breast Cancer Market Dynamics: ER+/HER2- Breast Cancer market drivers and ER+/HER2- Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
ER+/HER2- Breast Cancer Unmet Needs, KOL's views, Analyst's views, ER+/HER2- Breast Cancer Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. ER+/HER2- Breast Cancer Patient Share (%) Overview at a Glance
5. ER+/HER2- Breast Cancer Market Overview at a Glance
6. ER+/HER2- Breast Cancer Disease Background and Overview
7. ER+/HER2- Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of ER+/HER2- Breast Cancer
9. ER+/HER2- Breast Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. ER+/HER2- Breast Cancer Emerging Therapies
12. ER+/HER2- Breast Cancer Market Outlook
13. Country-Wise ER+/HER2- Breast Cancer Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. ER+/HER2- Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about ER+/HER2- Breast Cancer Market Outlook 2032 https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

ER+/HER2- Breast Cancer Pipeline Insights, DelveInsight

"ER+/HER2- Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the ER+/HER2- Breast Cancer market. A detailed picture of the ER+/HER2- Breast Cancer pipeline landscape is provided, which includes the disease overview and ER+/HER2- Breast Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.